

Table S1 Search strategy

Search No.	PubMed	Results	Embase	Results	Cochrane Trials	Results
#1	Stroke, Lacunar[mh] OR lacunar stroke*[tw] OR lacunar infarct*[tw] OR lacunar syndrome*[tw] OR ischemic stroke*[tw] OR ischaemic stroke*[tw] OR ischemic brain stroke*[tw] OR ischaemic brain stroke*[tw] OR brain ischemia*[tw] OR brain ischaemia*[tw] OR cerebral ischemia*[tw] OR cerebral ischaemia*[tw] OR cerebrovascular ischemia*[tw] OR cerebrovascular ischaemia*[tw] OR ischemic brain[tw] OR ischaemic brain[tw] OR ischemic encephalopath*[tw] OR ischaemic encephalopath*[tw]	111,773	('lacunar stroke'/de OR (lacunar NEAR/3 (stroke* OR infarct* OR syndrome*)):ti,ab OR (isch*mic NEAR/5 stroke*):ti,ab OR (brain NEAR/5 isch*mi*):ti,ab OR (cerebral NEAR/5 isch*mia*):ti,ab OR (cerebrovascular NEAR/5 isch*mia*):ti,ab OR (isch*mic NEAR/5 encephalopath*):ti,ab)	171,132	[mh "Stroke, Lacunar"] OR (lacunar NEAR/3 (stroke* OR infarct* OR syndrome*)):ti,ab OR (isch*mic NEAR/5 stroke*):ti,ab OR (brain NEAR/5 isch*mi*):ti,ab OR (cerebral NEAR/5 isch*mia*):ti,ab OR (cerebrovascular NEAR/3 isch*mia*):ti,ab OR (isch*mic NEAR/5 encephalopath*):ti,ab	14,082
#2	Brain Infarction[mh] OR brain infarct*[tw] OR brain stem infarct*[tw] OR brain venous infarct*[tw] OR cerebral infarct*[tw] OR cerebral artery infarct*[tw] OR cerebrovascular infarct*[tw] OR cortical infarct*[tw] OR subcortical infarct*[tw] OR hemisphere infarct*[tw] OR hemispheric infarct*[tw]	52,031	('brain infarction'/exp OR ((brain OR cerebral OR cerebrovascular OR cortical OR hemisphere) NEAR/5 infarct*):ti,ab)	93,661	[mh "Cerebral Infarction"] OR ((brain OR cerebral OR cerebrovascular OR cortical OR hemisphere) NEAR/5 infarct*):ti,ab	4,878
#3	Ischemic Attack, Transient[mh] OR transient ischemic attack*[tw] OR transient ischaemic attack*[tw] OR transient brain ischemia*[tw] OR transient brain ischaemia*[tw] OR transient cerebral ischemia*[tw] OR transient cerebral ischaemia*[tw] OR (brain[tw] AND (TIA[tw] OR TIAs[tw]))	30,088	('transient ischemic attack'/exp OR (transient NEAR/5 isch*mic NEAR/5 attack*):ti,ab OR (transient NEAR/5 (brain OR cerebral) NEAR/5 isch*mia*):ti,ab OR (brain NEAR/5 (TIA OR TIAs)):ti,ab)	47,458	[mh "Ischemic Attack, Transient"] OR (transient NEAR/5 isch*mic NEAR/5 attack*):ti,ab OR (transient NEAR/5 (brain OR cerebral) NEAR/5 isch*mia*):ti,ab OR (brain NEAR/5 (TIA OR TIAs)):ti,ab	2,660
#4	#1 OR #2 OR #3	160,882	#1 OR #2 OR #3	259,013	#1 OR #2 OR #3	18,119
#5	Platelet Aggregation Inhibitors[mh] OR platelet aggregation inhibitor*[tw] OR platelet antiaggregant*[tw] OR platelet anti-aggregant*[tw] OR platelet inhibitor*[tw] OR antiplatelet agent*[tw] OR antiplatelet drug*[tw] OR anti-platelet agent*[tw] OR anti-platelet drug*[tw] OR platelet antagonist*[tw] OR antithrombotic agent*[tw] OR anti-thrombotic agent*[tw] OR thrombocyte aggregation inhibitor*[tw]	43,502	('antithrombotic agent'/de OR ((platelet OR thrombocyte) NEAR/3 (inhibitor* OR antiaggregant* OR anti-aggregant* OR antagonist*)):ti,ab OR ((antiplatelet OR anti-platelet OR antithrombotic OR anti-thrombotic) NEAR/3 (drug* OR agent*)):ti,ab)	58,684	[mh "Platelet Aggregation Inhibitors"] OR ((platelet OR thrombocyte) NEAR/3 (inhibitor* OR antiaggregant* OR anti-aggregant* OR antagonist*)):ti,ab OR ((antiplatelet OR anti-platelet OR antithrombotic OR anti-thrombotic) NEAR/3 (drug* OR agent*)):ti,ab	5,954
#6	Aspirin[mh] OR aspirin[tw] OR acetylsalicylic acid[tw] OR acetyl salicylic acid[tw] OR acetosalicylic acid[tw] OR Acylpyrin[tw] OR Colfarit[tw] OR Ecotrin[tw] OR Endosprin[tw] OR Magnecyl[tw] OR Micristin[tw] OR Polopirin[tw] OR Polopiryna[tw] OR Solupsan[tw] OR Zorprin[tw] OR Acetysal[tw] OR Aloxiprimum[tw] OR Dispril[tw] OR Easprin[tw] OR Solprin[tw]	71,184	('acetylsalicylic acid'/de OR (aspirin OR 'acetylsalicylic acid' OR 'acetyl salicylic acid' OR 'acetosalicylic acid' OR Acylpyrin OR Colfarit OR Ecotrin OR Endosprin OR Magnecyl OR Micristin OR Polopirin OR Polopiryna OR Solupsan OR Zorprin OR Acetysal OR Aloxiprimum OR Dispril OR Easprin OR Solprin):ti,ab)	226,793	[mh Aspirin] OR (aspirin OR "acetylsalicylic acid" OR "acetyl salicylic acid" OR "acetosalicylic acid" OR Acylpyrin OR Colfarit OR Ecotrin OR Endosprin OR Magnecyl OR Micristin OR Polopirin OR Polopiryna OR Solupsan OR Zorprin OR Acetysal OR Aloxiprimum OR Dispril OR Easprin OR Solprin):ti,ab	14,748

Table S1 (continued)

Table S1 (continued)

Search No.	PubMed	Results	Embase	Results	Cochrane Trials	Results
#7	Ticlopidine[mh] OR ticlopidine[tw] OR ticlodix[tw] OR ticlodone[tw] OR 53-32C[tw] OR 5332C[tw] OR ticlid[tw]	11,945	ticlopidine/de OR (ticlopidine OR ticlodix OR ticlodone OR 53-32C OR 5332C OR ticlid):ti,ab	14,688	[mh Ticlopidine] OR (ticlopidine OR ticlodix OR ticlodone OR "53-32C" OR 5332C OR ticlid):ti,ab	2,635
#8	Clopidogrel[tw] OR SC 25989C[tw] OR SC 25990C[tw] OR SR 25989[tw] OR Iscover[tw] OR PCR-4099[tw] OR Plavix[tw]	14,755	clopidogrel/de OR (Clopidogrel OR SC-25989C OR SC-25990C OR SR-25989 OR Iscover OR PCR-4099 OR Plavix):ti,ab	62,606	[mh Clopidogrel] OR (Clopidogrel OR SC-25989C OR SC-25990C OR SR-25989 OR Iscover OR PCR-4099 OR Plavix):ti,ab	4,919
#9	Cilostazol[mh] OR Cilostazol[tw] OR OPC-13013[tw] OR Pletal[tw] OR pletaal[tw]	1,911	cilostazol/de OR (Cilostazol OR OPC-13013 OR Pletal OR pletaal):ti,ab	5,975	[mh Cilostazol] OR (Cilostazol OR OPC-13013 OR Pletal OR pletaal):ti,ab	802
#10	Ticagrelor[mh] OR Ticagrelor[tw] OR Brilique[tw] OR AZD 6140[tw] OR Brilinta[tw]	2,989	ticagrelor/de OR (Ticagrelor OR Brilique OR AZD-6140 OR Brilinta):ti,ab	9,772	[mh Ticagrelor] OR (Ticagrelor OR Brilique OR AZD-6140 OR Brilinta):ti,ab	1,706
#11	Prasugrel Hydrochloride[mh] OR Prasugrel[tw] OR CS 747[tw] OR Efient[tw] OR Effient[tw] OR LY 640315[tw]	2,532	prasugrel/de OR (Prasugrel OR CS-747 OR Efient OR Effient OR LY-640315):ti,ab	8,976	[mh "Prasugrel Hydrochloride"] OR (Prasugrel OR CS-747 OR Efient OR Effient OR LY-640315):ti,ab	1,057
#12	triflusal[tw] OR 2-acetoxy-4-trifluoromethylbenzoic acid[tw] OR Disgren[tw] OR tecnosal[tw] OR triflux[tw] OR aflen[tw]	192	triflusal/de OR (triflusal OR '2-acetoxy-4-trifluoromethylbenzoic acid' OR Disgren OR tecnosal OR triflux OR aflen):ti,ab	621	(triflusal OR "2-acetoxy-4-trifluoromethylbenzoic acid" OR Disgren OR tecnosal OR triflux OR aflen):ti,ab	113
#13	Dipyridamole[mh] OR Dipyridamole[tw] OR Dipyramidole[tw] OR Cerebrovase[tw] OR Persantine[tw] OR Persantin[tw] OR Curantil[tw] OR Curantyl[tw] OR Kurantil[tw] OR Miosen[tw] OR Novo-Dipiradol[tw] OR Antistenocardin[tw] OR Cléridium[tw] OR Cleridium[tw]	10,561	dipyridamole/de OR (Dipyridamole OR Dipyramidole OR Cerebrovase OR Persantine OR Persantin OR Curantil OR Curantyl OR Kurantil OR Miosen OR Novo-Dipiradol OR Antistenocardin OR Cléridium OR Cleridium):ti,ab	25,496	[mh Dipyridamole] OR (Dipyridamole OR Dipyramidole OR Cerebrovase OR Persantine OR Persantin OR Curantil OR Curantyl OR Kurantil OR Miosen OR Novo-Dipiradol OR Antistenocardin OR Cléridium OR Cleridium):ti,ab	1,299
#14	sarpogrelate[tw] OR MCI-9042[tw] MCI9042[tw] OR anplag[tw]	29	sarpogrelate/de OR (sarpogrelate OR MCI-9042 MCI9042 OR anplag):ti,ab	652	(sarpogrelate OR MCI-9042 MCI9042 OR anplag):ti,ab	95
#15	Placebos[mh] OR Control Groups[mh] OR placebo[tw] OR placebos[tw] OR control group*[tw]	689,855	placebo/de OR 'control group'/de OR (placebo* OR 'control group*'):ti,ab	1,126,149	[mh Placebos] OR [mh "Control Groups"] OR (placebo* OR "control group*"):ti,ab	471,321
#16	OR #5 to #15	793,523	OR #5 to #15	1,396,246	OR #5 to #15	485,357
#17	Secondary Prevention[mh] OR ((secondary[tw] OR relapse[tw] OR recurren*[tw]) AND preventi*[tw]) OR early therap*[tw]	169,633	('secondary prevention'/de OR ((secondary OR relapse OR recurren*) AND prevention*):ti,ab OR 'early therap*':ti,ab)	109,216	[mh "Secondary Prevention"] OR ((secondary OR relapse OR recurrence) AND prevention*):ti,ab OR "early therap*":ti,ab	24,628
#18	#4 AND #16 AND #17	2,322	#4 AND #16 AND #17	3,840	#4 AND #16 AND #17	791

Table S1 (continued)

Table S1 (continued)

Search No.	PubMed	Results	Embase	Results	Cochrane Trials	Results
#19	(Animals[mh] NOT Humans[mh]) OR Models, Animal[mh:noexp] OR Disease Models, Animal[mh] OR Animal Experimentation[mh]	4,935,274	(animal/exp NOT human/exp) OR 'animal model'/exp OR 'animal experiment'/exp OR 'animal cell'/ de OR 'animal tissue'/de OR 'in vitro study'/de OR 'nonhuman'/ de	9,510,924	Cochrane Reviews 18 Trials 773	
#20	#18 NOT #19	2,277	#18 NOT #19	3,640		
#21	Clinical Trial[pt] OR Clinical Trials as Topic[mh] OR Random Allocation[mh] OR Double-Blind Method[mh] OR Single-Blind Method[mh] OR Multicenter Study[pt] OR Multicenter Studies as Topic[mh] OR randomiz*[tw] OR randomis*[tw] OR randomly[tw] OR trial[tw] OR trials[tw] OR groups[tw] OR placebo[tw] OR placebos[tw] OR ((single*[tw] OR double*[tw] OR treb*[tw] OR tripl*[tw]) AND (blind*[tw] OR mask*[tw])) OR (random*[tw] AND (allocat*[tw] OR assign*[tw])) OR drug therapy[sh]	5,567,516	('clinical trial'/exp OR 'clinical trial (topic)'/exp OR randomization/ exp OR 'double blind procedure'/de OR 'single blind procedure'/de OR (randomiz* OR randomis* OR randomly OR trial OR trials OR groups OR placebo OR placebos):ti,ab OR ((single* OR double* OR treb* OR tripl*) AND (blind* OR mask*)):ti,ab OR (random* AND (allocat* OR assign*)):ti,ab OR 'drug therapy':lnk)	8,220,832		
#22	#20 AND #21	1,851	#20 AND #21	3,194	Trials	773

Table S2 Characteristics of the enrolled trials

Trial	Antiplatelet therapy regimens	F/U	Tx.	Patients	N	T	C	Male	Age	HTN	DM
1969 Acheson (94)	Dipyridamole vs Placebo	25M		Stroke/TIA	169	85	84	70%	58	59%	NC
1977 AITIA, Fields (76)	Aspirin (high) vs Placebo	6M		TIA	178	88	90	62%	60	47%	14%
1978 Canadian Coop (77)	Aspirin (high) vs Placebo	26M		TIA	283	144	139	67%	NC	NC	NC
1980 Reuther (78)	Aspirin (high) vs Placebo	24M		TIA	60	30	30	65%	58	50%	17%
1981 Pince J (102)	Aspirin+Dipyridamole vs Placebo	10D		IS	80	40	40	62%	66	NC	NC
1983 AICLA, Bousser (79)	Aspirin (high) vs Aspirin+Dipyridamole vs Placebo	36M		IS/TIA	604	198/ 202	204	70%	63	63%	22%
1983 Danish Coop (80)	Aspirin (high) vs Placebo	25M		TIA	203	101	102	73%	59	27%	NC
1983 Turpie (95)	Ticlopidine vs Placebo	16D		IS	53	27	26	40%	NC	NC	NC
1984 Tohgi (81)	Aspirin (high) vs Ticlopidine	12M		TIA	340	170	170	NC	NC	NC	NC
1985 ACCSG (82)	Aspirin+Dipyridamole vs Aspirin (high)	61M		TIA	890	448	442	67%	64	48%	15%
1985 Ross Russel (96)	Ticlopidine vs Placebo	3M		TIA	22	11	11	NC	NC	NC	NC
1987 Swedish Coop (83)	Aspirin (high) vs Placebo	24M		IS	505	253	252	62%	68	46%	17%
1989 CATS, Gent (97)	Ticlopidine vs Placebo	24M		IS	1,053	525	528	62%	65	68%	32%
1989 TASS, Hass (84)	Aspirin (high) vs Ticlopidine	40M		IS/TIA	3,069	1,529	1,540	65%	63	39%	20%
1990 ESPS (103)	Aspirin+Dipyridamole vs Placebo	24M		IS/TIA	2,500	1,250	1,250	58%	63	37%	NC
1990 Kaye (85)	Aspirin+Dipyridamole vs Aspirin (high)	2W	<72h	IS	183	88	95	38%	NC	NC	NC

Table S2 (continued)

Table S2 (continued)

Trial	Antiplatelet therapy regimens	F/U	Tx.	Patients	N	T	C	Male	Age	HTN	DM
1991 DUTCH TIA (41)	Aspirin (very low) vs Aspirin (low to medium)	31M		IS/TIA	3,131	1,555	1,576	65%	NC	42%	8%
1991 SALT (42)	Aspirin (low to medium) vs Placebo	29M		IS/TIA	1,360	676	684	66%	67	48%	13%
1991 UK-TIA, Farrell (61)	Aspirin (low to medium) vs Aspirin (high) vs Placebo	50M		IS/TIA	2,435	806/815	814	73%	60	40%	5%
1995 MAST-I (27)	Aspirin (low to medium) vs Placebo	10D	<6h	IS	309	153	156	53%	NC	NC	NC
1995 Smirne (62)	Triflusal vs Aspirin (low to medium)	6M		TIA	183	90	93	58%	66	51%	10%
1996 CAPRIE (63)	Aspirin (low to medium) vs Clopidogrel	14M		IS	6,428	3,233	3,198	64%	65	65%	25%
1996 ESPS2, Diener (43)	Aspirin+Dipyridamole vs Aspirin (low to medium) vs Dipyridamole vs Placebo	24M		IS/TIA	6,602	1,650/1,649/1,654	1,649	58%	66	61%	16%
1997 CAST, Chen (44)	Aspirin (low to medium) vs Placebo	1M	<48h	IS	20,655	10,335	10,320	64%	63	25%	NC
1997 IST (64)	Aspirin (low to medium) vs Placebo	2W	<48h	IS	19,435	9,720	9,715	54%	70	82%	NC
2000 CSPS, Gotoh (87)	Cilostazol vs Placebo	22M		IS	1,067	533	534	66%	65	61%	25%
2003 AAASPS, Gorelick (86)	Ticlopidine vs Aspirin (high)	24M		IS	1,809	902	907	47%	61	86%	41%
2003 TACIP, Matias-Guiu (65)	Triflusal vs Aspirin (low to medium)	30M		IS/TIA	2,107	1,055	1,052	66%	64	62%	25%
2003 TOPALS, Ito (98)	Aspirin+Ticlopidine vs Ticlopidine	19M		IS/TIA	270	132	138	65%	67	47%	23%
2004 MATCH, Diener (100)	Aspirin+Clopidogrel vs Clopidogrel	18M		IS/TIA	7,599	3,797	3,802	63%	66	78%	68%
2004 TAPIRSS, Culebras (66)	Triflusal vs Aspirin (low to medium)	19M		IS/TIA	429	213	216	69%	65	71%	19%
2005 CARESS, Markus (45)	Aspirin+Clopidogrel vs Aspirin (low to medium)	1W		IS/TIA	107	51	56	70%	66	65%	32%
2005 Chairangsarit (67)	Aspirin+Dipyridamole vs Aspirin (low to medium)	6M	<48h	IS	38	20	18	53%	64	50%	32%
2005 PLUTO-Stroke, Serebruany (46)	Aspirin+Clopidogrel vs Aspirin (low to medium)	1M		IS	70	35	35	50%	68	50%	39%
2005 TOSS, Kwon (47)	Aspirin+Cilostazol vs Aspirin (low to medium)	6M		IS	135	67	68	61%	62	58%	40%
2006 ESPRIT, Halkes (73)	Aspirin+Dipyridamole vs Aspirin (low to medium)	42M		IS/TIA	2,739	1,363	1,376	66%	63	60%	19%
2006 FASTER, Kennedy (19)	Aspirin+Clopidogrel vs Aspirin (low to medium)	3M	<24h	IS/TIA	392	198	194	53%	68	51%	11%
2008 CASISP, Huang (48)	Cilostazol vs Aspirin (low to medium)	15M		IS	719	360	359	69%	60	79%	18%
2008 Fukuuchi (88)	Clopidogrel vs Ticlopidine	12M		IS	1,151	573	578	73%	65	68%	19%
2008 PRoFESS, Sacco (89)	Aspirin+Dipyridamole vs Clopidogrel	30M		IS	20,332	10,181	10,151	64%	66	74%	29%
2008 S-ACCESS, Shinohara (49)	Sarpogrelate vs Aspirin (low to medium)	19M		IS	1,510	752	758	72%	65	70%	28%
2008 Serebruany (90)	Aspirin+Dipyridamole vs Aspirin+Clopidogrel vs Clopidogrel	1M		TIA	60	20/20	20	64%	61	70%	100%
2009 Guo (50)	Cilostazol vs Aspirin (low to medium)	12M		IS	68	34	34	35%	60	NC	NC
2009 Uchiyama (91)	Clopidogrel vs Ticlopidine	12M		IS	1,869	941	928	72%	64	70%	22%
2010 CLAIR, Wong (51)	Aspirin+Clopidogrel vs Aspirin (low to medium)	1W	<72h	IS/TIA	98	46	52	78%	59	64%	38%
2010 CSPS2, Shinohara (52)	Cilostazol vs Aspirin (low to medium)	29M		IS	2,757	1,379	1,378	72%	63	74%	29%

Table S2 (continued)

Table S2 (continued)

Trial	Antiplatelet therapy regimens	F/U	Tx.	Patients	N	T	C	Male	Age	HTN	DM
2010 EARLY, Dengler (20)	Aspirin+Dipyridamole vs Aspirin (low to medium)	1W	<24h	IS/TIA	543	283	260	63%	69	74%	24%
2011 CAIST, Lee (68)	Cilostazol vs Aspirin (low to medium)	3M	<48h	IS	458	231	227	62%	63	65%	35%
2011 CHARISMA, Hankey (28)	Aspirin+Clopidogrel vs Aspirin (low to medium)	25M		IS/TIA	4,320	2,157	2,163	63%	65	76%	29%
2011 JASAP, Uchiyama (53)	Aspirin+Dipyridamole vs Aspirin (low to medium)	15M		IS	1,291	652	639	72%	66	89%	41%
2011 TOSS2, Kwon (99)	Aspirin+Cilostazol vs Aspirin+Clopidogrel	7M		IS	457	232	225	52%	65	72%	43%
2012 Nakamura (69)	Aspirin+Cilostazol vs Aspirin (low to medium)	6M	<48h	IS	76	38	38	74%	66	82%	35%
2012 SPS3, Benavente (70)	Aspirin+Clopidogrel vs Aspirin (low to medium)	40M		IS	3,020	1,517	1,503	63%	63	75%	37%
2013 CHANCE, Wang (21)	Aspirin+Clopidogrel vs Aspirin (low to medium)	3M	<24h	IS/TIA	5,170	2,584	2586	67%	63	66%	22%
2013 ECLIPse, Han (54)	Aspirin+Cilostazol vs Aspirin (low to medium)	3M		IS	203	100	103	75%	65	57%	29%
2014 Yi (71)	Aspirin+Clopidogrel vs Aspirin (low to medium)	1M	<48h	IS	574	286	288	55%	69	73%	38%
2015 CATHARSIS, Uchiyama (55)	Aspirin+Cilostazol vs Aspirin (low to medium)	24M		IS	163	83	80	66%	68	77%	37%
2015 He (72)	Aspirin+Clopidogrel vs Aspirin (low to medium)	2W	<72h	IS/TIA	690	343	347	57%	62	68%	42%
2015 Yi (74)	Aspirin+Clopidogrel vs Aspirin (low to medium)	6M	<48h	IS	979	490	489	56%	69	71%	34%
2016 COMPRESS, Hong (56)	Aspirin+Clopidogrel vs Aspirin (low to medium)	1M	<48h	IS	358	178	180	64%	67	67%	33%
2016 SOCRATES, Johnston (57)	Ticagrelor vs Aspirin (low to medium)	3M	<24h	IS/TIA	13,199	6,589	6,610	59%	65	74%	25%
2017 MAESTRO, Han (92)	Triflusal vs Clopidogrel	32M		IS	784	391	393	68%	61	61%	29%
2017 Zuo (58)	Aspirin+Clopidogrel vs Aspirin (low to medium)	3M		IS/TIA	200	66/66	68	61%	61	65%	32%
2018 PICASSO, Kim (59)	Cilostazol vs Aspirin (low to medium)	23M		IS/TIA	1,534	766	768	62%	65	89%	33%
2018 POINT, Johnston (22)	Aspirin+Clopidogrel vs Aspirin (low to medium)	3M	<12h	IS/TIA	4,881	2,432	2,449	56%	65	70%	28%
2019 ADS, Aoki (75)	Aspirin+Cilostazol vs Aspirin (low to medium)	3M	<48h	IS	1201	600	601	66%	69	76%	32%
2019 PRASTRO-I, Ogawa (93)	Prasugrel vs Clopidogrel	25M		IS	3,747	1,885	1,862	79%	62	80%	33%
2019 PRINCE, Wang (101)	Aspirin+Ticagrelor vs Aspirin+Clopidogrel	3M	<24h	IS/TIA	675	336	339	74%	60	61%	25%
2020 THALES, Johnston (60)	Aspirin+Ticagrelor vs Aspirin (low to medium)	1M	<24h	IS/TIA	11,016	5,523	5,493	62%	65	78%	29%

F/U, follow-up period; Tx., time interval from symptom onset to treatment initiation; N, number of total participants; T, number of treatment groups; C, number of comparator groups; IS, ischemic stroke; TIA, transient ischemic stroke; M, month; D, day; W, week




Figure S1 Risk of bias summaries depicted using colors (red: high risk; green: low risk; yellow: unclear).




Figure S2 Graph of the total risk of bias of the entire network meta-analysis

Table S7 League table of antiplatelet regimens with the relative risks and 95% credible intervals for all bleeding events

Antiplatelet Regimens	A_1	A_2	A_3	A_C	A_Ci	A_D	A_Ti	Cilostazol	Clopidogrel	Dipyridamole	Placebo	Prasugrel	Sarpogrelate	Ticagrelor	Ticlopidine	Triflusal
A_1		0.65(0.37,1.15)	0.47(0.22,0.90)	0.33(0.18,0.62)	0.42(0.12,1.50)	0.64(0.33,1.15)	0.21(0.09,0.50)	1.02(0.55,1.97)	0.79(0.41,1.58)	1.11(0.51,2.31)	0.97(0.51,1.82)	0.77(0.32,1.83)	0.96(0.44,2.09)	0.50(0.23,1.10)	0.55(0.25,1.16)	1.09(0.57,2.26)
A_2	1.52(0.86,2.65)		0.72(0.47,1.04)	0.51(0.40,0.65)	0.64(0.21,2.02)	0.98(0.72,1.23)	0.32(0.17,0.61)	1.56(1.17,2.12)	1.21(0.84,1.77)	1.69(0.99,2.77)	1.48(1.09,1.99)	1.17(0.60,2.28)	1.46(0.84,2.52)	0.77(0.43,1.34)	0.84(0.50,1.38)	1.67(1.14,2.59)
A_3	2.09(1.10,4.34)	1.37(0.96,2.10)		0.71(0.46,1.15)	0.89(0.28,2.97)	1.34(0.90,2.02)	0.45(0.22,0.97)	2.16(1.39,3.63)	1.67(1.03,2.91)	2.34(1.29,4.34)	2.05(1.40,3.09)	1.61(0.79,3.56)	2.01(1.06,4.09)	1.06(0.55,2.18)	1.16(0.79,1.78)	2.31(1.39,4.30)
A_C	2.94(1.60,5.41)	1.92(1.52,2.44)	1.39(0.86,2.14)		1.24(0.41,4.01)	1.89(1.31,2.56)	0.63(0.35,1.13)	3.03(2.10,4.43)	2.33(1.61,3.45)	3.25(1.84,5.64)	2.85(1.95,4.17)	2.27(1.17,4.43)	2.82(1.55,5.10)	1.48(0.81,2.71)	1.63(0.92,2.80)	3.22(2.12,5.25)
A_Ci	2.34(0.66,8.00)	1.55(0.49,4.57)	1.11(0.33,3.52)	0.80(0.24,2.43)		1.50(0.46,4.57)	0.51(0.13,1.77)	2.43(0.76,7.53)	1.88(0.56,5.98)	2.61(0.75,8.75)	2.29(0.70,7.17)	1.81(0.49,6.55)	2.27(0.63,7.61)	1.19(0.33,4.05)	1.30(0.38,4.34)	2.62(0.77,8.33)
A_D	1.54(0.86,2.97)	1.01(0.80,1.37)	0.74(0.49,1.10)	0.52(0.38,0.75)	0.66(0.21,2.13)		0.33(0.17,0.67)	1.59(1.12,2.45)	1.23(0.87,1.87)	1.72(1.02,2.94)	1.51(1.08,2.20)	1.19(0.63,2.41)	1.49(0.83,2.82)	0.78(0.43,1.49)	0.86(0.51,1.47)	1.70(1.12,2.88)
A_Ti	4.61(1.99,10.5)	3.03(1.62,5.69)	2.20(1.02,4.48)	1.57(0.87,2.82)	1.96(0.56,7.17)	2.97(1.47,5.64)		4.75(2.40,9.58)	3.70(1.86,7.53)	5.15(2.25,11.3)	4.52(2.24,8.93)	3.56(1.47,8.75)	4.48(1.94,10.3)	2.33(1.01,5.52)	2.56(1.13,5.69)	5.10(2.5,11.02)
Cilostazol	0.97(0.50,1.80)	0.63(0.46,0.84)	0.46(0.27,0.71)	0.32(0.22,0.47)	0.41(0.13,1.31)	0.62(0.40,0.89)	0.21(0.10,0.41)		0.77(0.48,1.23)	1.07(0.58,1.88)	0.94(0.63,1.38)	0.74(0.36,1.53)	0.93(0.49,1.72)	0.49(0.25,0.91)	0.53(0.29,0.92)	1.06(0.65,1.78)
Clopidogrel	1.25(0.63,2.43)	0.82(0.56,1.18)	0.59(0.34,0.96)	0.42(0.28,0.62)	0.53(0.16,1.76)	0.81(0.53,1.13)	0.26(0.13,0.53)	1.29(0.81,2.06)		1.39(0.74,2.51)	1.22(0.75,1.90)	0.96(0.56,1.67)	1.20(0.61,2.32)	0.63(0.32,1.24)	0.69(0.37,1.24)	1.38(0.88,2.25)
Dipyridamole	0.89(0.43,1.93)	0.58(0.36,1.00)	0.42(0.22,0.77)	0.30(0.17,0.54)	0.38(0.11,1.33)	0.57(0.33,0.97)	0.19(0.08,0.44)	0.92(0.52,1.70)	0.71(0.39,1.35)		0.87(0.51,1.51)	0.69(0.30,1.60)	0.86(0.41,1.88)	0.45(0.21,0.98)	0.49(0.25,0.97)	0.98(0.53,1.97)
Placebo	1.02(0.54,1.94)	0.67(0.50,0.91)	0.48(0.32,0.71)	0.34(0.23,0.51)	0.43(0.13,1.41)	0.65(0.45,0.92)	0.22(0.11,0.44)	1.05(0.72,1.58)	0.81(0.52,1.31)	1.13(0.65,1.94)		0.78(0.39,1.63)	0.98(0.52,1.85)	0.51(0.27,0.98)	0.56(0.34,0.91)	1.12(0.70,1.93)
Prasugrel	1.29(0.54,3.03)	0.84(0.43,1.65)	0.61(0.28,1.25)	0.44(0.22,0.85)	0.54(0.15,2.02)	0.83(0.41,1.57)	0.28(0.11,0.67)	1.33(0.65,2.74)	1.03(0.59,1.77)	1.44(0.62,3.25)	1.26(0.61,2.56)		1.24(0.52,2.94)	0.65(0.27,1.56)	0.72(0.31,1.60)	1.42(0.71,3.00)
Sarpogrelate	1.03(0.47,2.26)	0.68(0.39,1.17)	0.49(0.24,0.93)	0.35(0.19,0.64)	0.43(0.13,1.57)	0.66(0.35,1.19)	0.22(0.09,0.51)	1.07(0.58,2.01)	0.82(0.43,1.62)	1.15(0.53,2.41)	1.01(0.53,1.89)	0.80(0.33,1.91)		0.52(0.23,1.14)	0.57(0.26,1.19)	1.14(0.59,2.32)
Ticagrelor	1.96(0.90,4.30)	1.29(0.74,2.27)	0.94(0.45,1.79)	0.67(0.36,1.22)	0.83(0.24,2.94)	1.27(0.66,2.30)	0.42(0.18,0.98)	2.02(1.09,3.89)	1.57(0.80,3.09)	2.20(1.01,4.61)	1.92(1.01,3.59)	1.52(0.64,3.66)	1.89(0.87,4.17)		1.09(0.51,2.29)	2.17(1.12,4.48)
Ticlopidine	1.79(0.85,3.85)	1.18(0.72,1.97)	0.85(0.56,1.25)	0.61(0.35,1.07)	0.76(0.22,2.62)	1.15(0.67,1.93)	0.39(0.17,0.87)	1.85(1.07,3.35)	1.43(0.80,2.68)	2.00(1.02,3.93)	1.75(1.09,2.85)	1.38(0.62,3.22)	1.73(0.83,3.70)	0.91(0.43,1.96)		1.98(1.08,3.89)
Triflusal	0.90(0.44,1.75)	0.59(0.38,0.87)	0.43(0.23,0.71)	0.31(0.19,0.47)	0.38(0.12,1.28)	0.58(0.34,0.88)	0.19(0.09,0.39)	0.93(0.55,1.51)	0.72(0.44,1.13)	1.01(0.50,1.85)	0.88(0.51,1.42)	0.70(0.33,1.39)	0.87(0.42,1.67)	0.45(0.22,0.89)	0.50(0.25,0.92)	

A_1, very low dose aspirin; A_2, low to medium dose aspirin; A_3, high dose aspirin; A_C, aspirin plus clopidogrel; A_Ci, aspirin plus cilostazol; A_D, aspirin plus dipyridamole; A_Ti, aspirin plus ticagrelor.

Table S8 Surface under the cumulative ranking curve (SUCRA) values and ranks

Antiplatelet Regimens	Recurrent stroke		Recurrent ischemic stroke		Composite vascular events		Major bleeding		All bleeding events	
	SUCRA	Rank	SUCRA	Rank	SUCRA	Rank	SUCRA	Rank	SUCRA	Rank
Aspirin (very low dose)	-	-	-	-	0.3613	12	0.4971	8	0.7662	4
Aspirin (low to medium dose)	0.2742	13	0.3496	11	0.2799	13	0.2748	13	0.4321	9
Aspirin (high dose)	0.3649	10	0.3098	12	0.4786	11	0.2319	14	0.2220	14
Cilostazol	0.9199	1	0.8292	2	0.8587	2	0.8954	1	0.8075	3
Clopidogrel	0.6928	5	0.6121	6	0.6095	7	0.4792	9	0.5981	7
Dipyridamole	0.2228	14	0.1217	15	0.1833	16	0.8207	3	0.8433	2
Prasugrel	0.6740	6	0.4871	10	0.6319	5	0.6740	6	0.5692	8
Sarpogrelate	0.1694	15	0.1458	14	0.2242	14	-	-	0.7384	6
Ticagrelor	0.5114	9	0.5861	8	0.5125	10	0.4457	10	0.2815	12
Ticlopidine	0.5686	8	0.6635	4	0.6151	6	0.7604	4	0.3325	11
Triflusal	0.3148	11	0.2910	13	0.2198	15	0.8413	2	0.8532	1
Aspirin + Cilostazol	0.6998	4	0.5931	7	0.5131	9	0.2994	12	0.2637	13
Aspirin + Clopidogrel	0.8249	2	0.8933	1	0.7918	3	0.0736	15	0.1003	15
Aspirin + Dipyridamole	0.6479	7	0.6324	5	0.6735	4	0.3577	11	0.4119	10
Aspirin + Ticagrelor	0.7238	3	0.8166	3	0.9515	1	0.0067	16	0.0181	16
Aspirin + Ticlopidine	0.3084	12	0.5734	9	0.5142	8	0.6905	5	-	-




Figure S3 Surface under the cumulative ranking curve (SUCRA) rankograms for the antiplatelet regimens for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events.




Figure S4 Inconsistency assessments using the node-splitting method for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events. Abbreviations: A_2, aspirin (low to medium dose); A_3, aspirin (high dose); A_C, aspirin plus clopidogrel; A_Ci, aspirin plus cilostazol; A_D, aspirin plus dipyridamole; A_T, aspirin plus ticagrelor.




Figure S5 Funnel plots of the antiplatelet regimens of the enrolled trials. The symmetrical shape of the funnel plots demonstrates that there is no evidence of publication bias in this network meta-analysis for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events.




Figure S6 Forrest plots of the antiplatelet regimens compared with aspirin in the subgroup analysis (< 72 hours) for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, and (D) major bleeding events.




Figure S7 Forrest plots of the antiplatelet regimens compared with aspirin in the subgroup analysis (> 72 hours) for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events.




Figure S8 Forrest plots of the antiplatelet regimens compared with aspirin in the subgroup analysis for large artery atherosclerosis for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events.




Figure S9 Forrest plots of the antiplatelet regimens compared with aspirin in the subgroup analysis for small vessel occlusion for (A) recurrent stroke, (B) recurrent ischemic stroke, and (C) composite outcomes.




Figure S10 Forrest plots of the antiplatelet regimens compared with aspirin in the subgroup analysis for dual anti-platelet therapy, for (A) recurrent stroke, (B) recurrent ischemic stroke, (C) composite outcomes, (D) major bleeding events, and (E) all bleeding events.